The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

Diabetes Care

Volumn 24, Issue 6, 2001, Pages 989-994

  Chiasson, Jean Louis ^a   Naditch, Lisa ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCOSAMINE; GLYCOSYLATED HEMOGLOBIN; IMINOSUGAR; INSULIN; METFORMIN; MIGLITOL; PLACEBO;

ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RACE; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLUCOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMINO PYRANOSES; INSULIN; MALE; METFORMIN; MIDDLE AGED; PLACEBOS; POSTPRANDIAL PERIOD;

EID: 0035374524     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.6.989     Document Type: Article

References (16)

1. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
2. U.K. Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes (UK-PDS 34). Lancet 352:854-865, 1998
3. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
4. Johansen K: Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 22:33-37, 1999
5. Campbell LK, White JR, Campbell RK: Acarbose: its role in the treatment of diabetes mellitus. Ann Pharmacother 30:1255-1262, 1996
6. Bischoff H: Pharmacology of α-glucosidase inhibition. Eur J Clin Invest 24 (Suppl. 3):3-10, 1994
7. Joubert PH, Venter HL, Foukaridis GN: The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycemic mechanism? BrJ Clin Pharmacol 30:391-396, 1990
8. Lebovitz HE: Oral antidiabetic agents: the emergence of α-glucosidase inhibitors. Drugs 44 (Suppl. 3):21-28, 1992
9. Holman RR, Steemson J, Turner RC: Postprandial glycaemic reduction by an α-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia. Diabetes Res 18:149-153, 1991
10. Heinz G, Komjati M, Korn A, Waldhausl W: Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes. Eur J Clin Pharmacol 37:33-36, 1989
11. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A: Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17:20-29, 1994
12. Spengler M, Hansel G, Boehme K: Efficacy of 6 months monotherapy with glucosidase inhibitor Acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM). Horm Metab Res (Suppl.) 26:50-51, 1992
13. Segal P, Feig PU, Schemthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C: The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 20:687-691, 1997
14. Escobar-Jimenez F, Barajas C, De Leiva A, Cano FJ, Masoliver R, Herrera-Pombo JL, Hernandez-Mijares A, Pinon F, de la Calle H, Tebar J, Soler J, Cobos A, Guardiola E, and the Miglitol Collaborative Group: Efficacy and tolerability of miglitol in the treatment of patients with non-insulin-dependent diabetes mellitus. Curr Ther Res 56:258-268, 1995
15. Saunier B, Kilker RD Jr, Tkacz JS, Quaroni A, Herscovics A: Inhibition of N-linked complex oligosaccharide formation by 1-deoxynojirimycin, an inhibitor of processing glucosidases. J Biol Chem 257:14155-14161, 1982
16. Scott LJ, Spencer CM: Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 59:521-549, 2000